Biocon Biologics Archives - Page 3 of 6 - Express Pharma

Serum Institute to invest $68 million in Oxford Biomedica

Inter-changeable designation for Semglee in the US is a milestone achievement for Biocon Biologics

Approval of first interchangeable biosimilar insulin to increase competition with payer contracts: GlobalData

Biocon Biologics and Viatris receive US FDA approval for maiden interchangeable biosimilar Semglee

Biocon Biologics and Adagio Therapeutics to develop antibody treatment for COVID-19

Biocon Biologics, Viatris get EC approval for biosimilar Bevacizumab

Biocon Biologics appoints susheel Umesh as chief commercial officer for emerging mkts

Biocon Biologics promotes Shreehas Tambe to deputy chief executive officer

Biocon Biologics and Viatris get CHMP Nod for Abevmy

Biocon Biologics partners with IDF to improve access to insulins